thromboxane a synthase

Summary

Summary: An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5.

Top Publications

  1. ncbi Molecular cloning of human platelet thromboxane A synthase
    C Yokoyama
    Department of Pharmacology, National Cardiovascular Center Research Institute, Osaka, Japan
    Biochem Biophys Res Commun 178:1479-84. 1991
  2. ncbi [Thromboxane A2 synthase inhibitor and receptor antagonist]
    K Minoguchi
    First Department of Internal Medicine, Showa University School of Medicine
    Nippon Rinsho 59:1986-91. 2001
  3. ncbi The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity
    Won Hwan Park
    Department of Biochemistry, Dongguk University COM, Kyungbuk Kyungju 780 714, South Korea
    Int Immunopharmacol 3:971-8. 2003
  4. ncbi Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate
    Sabine Pestel
    Institut fur Biochemie und Molekulare Zellbiologie, Georg August Universitat Gottingen, Humboldtallee 23, D 37073 Gottingen, Germany
    Biochem Pharmacol 66:643-52. 2003
  5. ncbi A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors
    Catherine Michaux
    Laboratoire Chimie Moléculaire Structurale, Facultes Universitaires N D de la Paix, 61, rue de Bruxelles, B 5000, Namur, Belgium
    Eur J Med Chem 38:703-10. 2003
  6. ncbi Thromboxane A2 inhibition: therapeutic potential in bronchial asthma
    Jean Michel Dogne
    Department of Medicinal Chemistry, University of Liege, Avenue de l Hopital 1, B36, B 4000 Liege, Belgium
    Am J Respir Med 1:11-7. 2002
  7. ncbi Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism
    Alexandre Ghuysen
    Hemodynamics Research Laboratory, University of Liege, Belgium
    J Pharmacol Exp Ther 310:964-72. 2004
  8. ncbi Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway
    Dong Ju Son
    College of Natural Sciences, Soonchunhyang University, Asan 336 745, South Korea
    Prostaglandins Leukot Essent Fatty Acids 71:25-31. 2004
  9. ncbi Functional role of NADPH oxidase in activation of platelets
    Stefan Chlopicki
    Department of Experimental Pharmacology, Jagiellonian University Medical College, Krakow, Poland
    Antioxid Redox Signal 6:691-8. 2004
  10. ncbi Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobili
    Yong Ri Jin
    College of Pharmacy, Chungbuk National University, 48 Gaesin dong, Heungduk gu, Cheongju, Chungbuk, 361 763, Korea
    J Pharmacol Exp Ther 312:214-9. 2005

Detail Information

Publications169 found, 100 shown here

  1. ncbi Molecular cloning of human platelet thromboxane A synthase
    C Yokoyama
    Department of Pharmacology, National Cardiovascular Center Research Institute, Osaka, Japan
    Biochem Biophys Res Commun 178:1479-84. 1991
    Complementary DNA coding for thromboxane A synthase was amplified by polymerase chain reaction using primers synthesized according to the partial amino acid sequences of human platelet thromboxane A synthase (Nüsing, R...
  2. ncbi [Thromboxane A2 synthase inhibitor and receptor antagonist]
    K Minoguchi
    First Department of Internal Medicine, Showa University School of Medicine
    Nippon Rinsho 59:1986-91. 2001
    ..Therefore, these results suggest that TxA2 synthase inhibitor and receptor antagonist are useful for the treatment with symptomatic patients who had already been treated with inhaled corticosteroids...
  3. ncbi The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity
    Won Hwan Park
    Department of Biochemistry, Dongguk University COM, Kyungbuk Kyungju 780 714, South Korea
    Int Immunopharmacol 3:971-8. 2003
    ..In conclusion, GBH suppressed PLC in a dose-dependent manner, and may have pharmaceutical applications. These data suggest that GBH extracts merit investigation as a potential anti-atherosclerogenic agent in humans...
  4. ncbi Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate
    Sabine Pestel
    Institut fur Biochemie und Molekulare Zellbiologie, Georg August Universitat Gottingen, Humboldtallee 23, D 37073 Gottingen, Germany
    Biochem Pharmacol 66:643-52. 2003
    ..In contrast, they did not interfere with PGD(2)-dependent glucose metabolism, suggesting an independent mechanism for the inhibition of glucose output from the liver...
  5. ncbi A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors
    Catherine Michaux
    Laboratoire Chimie Moléculaire Structurale, Facultes Universitaires N D de la Paix, 61, rue de Bruxelles, B 5000, Namur, Belgium
    Eur J Med Chem 38:703-10. 2003
    ..Such a model could be used to design new leads possessing the same pharmacological profile and to improve the activity of our compounds...
  6. ncbi Thromboxane A2 inhibition: therapeutic potential in bronchial asthma
    Jean Michel Dogne
    Department of Medicinal Chemistry, University of Liege, Avenue de l Hopital 1, B36, B 4000 Liege, Belgium
    Am J Respir Med 1:11-7. 2002
    ..Large scale clinical trials are necessary to further define the role of thromboxane modulators in the treatment of patients with asthma...
  7. ncbi Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism
    Alexandre Ghuysen
    Hemodynamics Research Laboratory, University of Liege, Belgium
    J Pharmacol Exp Ther 310:964-72. 2004
    ..We conclude that in this animal model of acute pulmonary embolism, infusion of BM-573 reduced pulmonary vasoconstriction. As a result, right ventricular-vascular coupling values were maintained at a maximal efficiency level...
  8. ncbi Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway
    Dong Ju Son
    College of Natural Sciences, Soonchunhyang University, Asan 336 745, South Korea
    Prostaglandins Leukot Essent Fatty Acids 71:25-31. 2004
    ..These results suggest that the antiplatelet activity of GTC may be due to the inhibition of TXA2 formation through the inhibition of AA liberation and TXA2 synthase...
  9. ncbi Functional role of NADPH oxidase in activation of platelets
    Stefan Chlopicki
    Department of Experimental Pharmacology, Jagiellonian University Medical College, Krakow, Poland
    Antioxid Redox Signal 6:691-8. 2004
    ....
  10. ncbi Antiplatelet activity of J78 (2-Chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobili
    Yong Ri Jin
    College of Pharmacy, Chungbuk National University, 48 Gaesin dong, Heungduk gu, Cheongju, Chungbuk, 361 763, Korea
    J Pharmacol Exp Ther 312:214-9. 2005
    ..Taken together, these results suggest that the antiplatelet activity of J78 may be mediated by TXA(2) receptor blockade with TXA(2) synthase inhibition and suppression of cytosolic Ca(2+) mobilization...
  11. ncbi Inherited defects in platelet signaling mechanisms
    A Koneti Rao
    Department of Medicine, Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA
    Semin Thromb Hemost 30:525-35. 2004
    ..There is a pressing need for a concerted effort to delineate the molecular mechanisms in the large group of patients with impaired platelet function who represent an untapped reservoir of new information into normal platelet function...
  12. ncbi In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist
    Julien Hanson
    Natural and Synthetic Drugs Research Centre, Department of Pharmacy, Laboratory of Medicinal Chemistry, University of Liege, 1, Av de l Hôpital, 4000 Liege, Belgium
    J Pharmacol Exp Ther 313:293-301. 2005
    ..These results suggest that BM-613 could be a potential therapeutic drug for thrombotic disorders...
  13. ncbi Testosterone treatment increases thromboxane function in rat cerebral arteries
    Rayna J Gonzales
    Department of Pharmacology, College of Medicine, Univ of California, Irvine, CA 92697 4625, USA
    Am J Physiol Heart Circ Physiol 289:H578-85. 2005
    ..The effect of in vivo testosterone on cerebrovascular TxA2 synthase, observed here after chronic hormone administration, may contribute to the risk of vasospasm and thrombosis related to cerebrovascular disease...
  14. ncbi Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse
    Syed R Baber
    Department of Pharmacology, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112, USA
    Am J Physiol Heart Circ Physiol 289:H1476-87. 2005
    ..The present data suggest that COX-1- or COX-2-derived prostanoids do not modulate responses to angiotensin II or other vasoactive agents and that prostanoid responses are similar in CD-1 and C57BL/6 and in male and female mice...
  15. ncbi Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice
    Shinsuke Murakami
    Department of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Osaka 565 8565, Japan
    Am J Physiol Lung Cell Mol Physiol 290:L59-65. 2006
    ....
  16. ncbi Endothelium-derived prostaglandin H2 evokes the stretch-induced contraction of rabbit pulmonary artery
    Maki Saito
    Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka City, Shizuoka 422 8526, Japan
    Eur J Pharmacol 467:151-61. 2003
    ..The results suggested that prostaglandin H(2) and thromboxane A(2), either released from endothelium by mechanical stretch or by acetylcholine, produced contraction of rabbit pulmonary artery in a RGD-independent manner...
  17. ncbi Role for thromboxane A2 from glomerular thrombi in nephropathy with type 2 diabetic rats
    Michiaki Okumura
    Department of Internal Medicine, Osaka City General Hospital, 2 13 22 Miyakojimahondori, Miyakojima ku, 534 0021, Osaka, Japan
    Life Sci 72:2695-705. 2003
    ..When platelet aggregation began, more TXA2 than before was released from the thrombi that formed, and the TXA2 contributed to the progress of nephropathy in this rat model of type 2 diabetes...
  18. ncbi Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles
    S Rolin
    Department of Pharmacy, University of Namur, FUNDP, 61 rue de Bruxelles, B-5000 Namur, Belgium
    Prostaglandins Leukot Essent Fatty Acids 65:67-72. 2001
    ..7 nM) contracted by U-46619. BM-573 (1 microM) completely reduced the platelet production of TXB(2)induced by arachidonic acid. Finally, BM-573 (30 mg/kg, per os) lost the diuretic properties of torasemide in rats...
  19. ncbi No effect of thromboxane A2 on the attachment of tumor cell lines MDA MB 231, DU145, and U937 to the basement membrane in an in-vitro model
    A Kleber
    Pharmazeutische und Medizinische Chemie, , , , Germany
    J Cancer Res Clin Oncol 127:751-4. 2001
    ..CONCLUSION: These data indicate that TxA2 might not be involved in the attachment of tumor cell lines to the basement membrane...
  20. ncbi Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets
    Roberta Vezza
    Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, USA
    Thromb Haemost 87:114-21. 2002
    ..These data show that endoperoxides and TXA2 mediate their effects on platelets acting on both, and the same, receptor isoform(s)...
  21. ncbi NQ-Y15 inhibits the calcium mobilization by elevation of cyclic AMP in rat platelets
    T S Chang
    College of Pharmacy, Seoul National University, Korea
    Biol Pharm Bull 24:480-3. 2001
    ..These results suggested that NQ-Y15 might inhibit the rise in [Ca2+]i in AA-treated rat platelets by increasing cAMP, which is involved in the inhibition of platelet activation...
  22. ncbi Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor
    J M Dogne
    Department of Pharmacy, University of Namur, Belgium
    J Pharm Pharmacol 53:669-80. 2001
    ..The pKa value and the crystallographic data of 14 were determined and used to propose an interaction model between the TXA2 antagonists related to torasemide and their receptor...
  23. ncbi Evaluation of the effects of anti-thromboxane agents in platelet-vessel wall interaction
    Carola Buccellati
    Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133, Milan, Italy
    Eur J Pharmacol 443:133-41. 2002
    ..These findings bear relevance in the development of novel anti-thrombotic drugs...
  24. ncbi Thromboxane A(2) causes retarded clearance of aggregated protein in glomeruli of nephritic mice
    T Nagao
    Department of Pharmacology, Faculty of Pharmacy, Meijo University, 150 Yagotoyama Tenpaku Ku, Nagoya 468 8503, Japan
    Eur J Pharmacol 413:271-9. 2001
    ..These findings suggest that thromboxane A(2) retards the clearance of aggregated protein in nephritic glomeruli and may contribute to the pathophysiology of glomerulonephritis...
  25. ncbi Production of thromboxane A2 and prostaglandin i2 affected by interaction of heat aggregated IgG, endothelial cells, and platelets in lupus nephritis
    Naoko Kaneko
    Division of Rheumatology and Clinical Immunology, Jichi Medical School, Minamikawachi Machi, Tochigi ken, Japan
    J Rheumatol 29:2106-13. 2002
    ..The effect of complement component C1q and a novel imidazole-type thromboxane A2 (TXA2) synthetase inhibitor, DP-1904, on this prostanoid metabolism change was also investigated...
  26. pmc Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction
    J P De La Cruz
    Department of Pharmacology and Therapeutics, School of Medicine, University of Malaga, 29071 Malaga, Spain
    Br J Pharmacol 137:1082-8. 2002
    ..4. In conclusion, the effect of specific blockage of TxS together with blockage of membrane receptors for TxA(2) can surpass the effect of ASA in inhibiting the platelet-subendothelium interaction in flow conditions...
  27. ncbi Induction of thromboxane A2 synthesizing enzymes in DMSO-induced granulocytic differentiation of HL-60 cells
    M Zaitsu
    Department of Pediatrics, Saga Medical School, Saga, Japan
    Prostaglandins Leukot Essent Fatty Acids 67:405-10. 2002
    ..These results demonstrated that TXB(2) production in granulocytic HL-60 cells was regulated at both the enzyme level of COX-2 and TXA(2) synthase...
  28. ncbi Effect of thromboxane A2 (TXA2) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs
    Y Yoshimi
    The Third Department of Internal Medicine, Kanazawa University School of Medicine, Japan
    Prostaglandins Other Lipid Mediat 65:1-9. 2001
    ..These findings suggest that other prostanoids such as PGE2, PGI2, PGD2 and PGF2alpha may not take an important role in the antiasthmatic effects of TXA2 modifiers...
  29. ncbi Selective neuromicrovascular endothelial cell death by 8-Iso-prostaglandin F2alpha: possible role in ischemic brain injury
    Sonia Brault
    Centre de Recherche de l Hôpital Sainte Justine, Department of Pediatrics and Pharmacology, Universite de Montreal, Montreal, Quebec, Canada
    Stroke 34:776-82. 2003
    ..Isoprostanes are major peroxidation products. Since microvascular dysfunction seems to contribute to ischemic encephalopathies, we studied the cytotoxicity of 8-iso-prostaglandin F2alpha (PGF2alpha) on cerebral microvascular cells...
  30. ncbi Thromboxanes: synthase and receptors
    R F Shen
    Department of Obstetrics, Gynecology, and Reproductive Sciences and Center for the Genetics of Asthma and Other Complex Diseases, University of Maryland School of Medicine, Baltimore 21201, USA
    J Biomed Sci 5:153-72. 1998
    ..Future investigation should shed light on detailed molecular signaling events specifying thromboxane A2 actions, and the genetic underpinning of the enzyme and the receptors in health and disease...
  31. ncbi Up-regulated thromboxane production in the rat liver with biliary obstruction does not contribute to promote hepatic injury
    Yukihiro Yokoyama
    Department of Surgery, Division of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Shock 29:688-91. 2008
    ..These results indicated that despite a highly increased production in the liver, TXA2 is not directly related to the hepatic injury in BDL rats...
  32. ncbi Anti-platelet activity of KR-32560, a novel sodium/hydrogen exchanger-1 inhibitor
    Kyung Sup Lee
    College of Pharmacy, Chungbuk National University, 12 Gaesin Dong, Heungduk gu, Cheongju 361 763, Korea
    Pharmacol Res 53:265-70. 2006
    ..Taken together, these observations suggest that the anti-platelet activity of KR-32560 may be mediated by the inhibition of cytoplasmic Ca2+ mobilization and AA liberation...
  33. ncbi Prostanoids as pharmacological targets in COPD and asthma
    Stephanie Rolin
    Department of Pharmacy, University of Namur, Rue de Bruxelles 61, B 5000 Namur, Belgium
    Eur J Pharmacol 533:89-100. 2006
    ..This article aims to provide an overview of the role of prostanoids and isoprostanes in the pathogenesis of COPD and asthma and to discuss the pharmacological strategies developed in prevention and/or treatment of these pathologies...
  34. pmc Thromboxane A2 inhibition of SKCa after NO synthase block in rat middle cerebral artery
    A J McNeish
    Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, UK
    Br J Pharmacol 151:441-9. 2007
    ....
  35. ncbi Endothelin-1 blockade prevents COX2 induction and TXA2 production in the fructose hypertensive rat
    Jihong Jiang
    Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada
    Can J Physiol Pharmacol 85:422-9. 2007
    ..Bosentan may prevent the development of hypertension in fructose-fed rats through inhibition of COX2 induction and subsequently the reduction in plasma TXA2...
  36. ncbi New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators
    Jean Michel Dogne
    Natural and Synthetic Drug Research Center, Medicinal Chemistry, University of Liege, 1, Av de l Hôpital, B 4000 Liege, Belgium
    Curr Med Chem 11:1223-41. 2004
    ..In this review, we will propose a description of the recently described thromboxane modulators of major interest from both a pharmacological and a chemical point of view...
  37. ncbi A change in the redox environment and thromboxane A2 production precede endothelial dysfunction in mice
    Marie Eve Gendron
    Department of Physiology, Faculty of Medicine, Universite de Montreal, Montreal Heart Institute, Montreal, Quebec, Canada
    Am J Physiol Heart Circ Physiol 293:H2508-15. 2007
    ..eNOS mRNA expression was significantly increased by catechin treatment. Our results suggest that an augmented production of TXA(2) and the associated change in redox regulation precede the development of the endothelial dysfunction...
  38. ncbi Antiplatelet effect of NQ12: a possible mechanism through the arachidonic acid cascade
    Yong Ri Jin
    Research Institute of Veterinary Medicine, CBITRC, Chungbuk National University, Cheongju, Korea
    J Pharmacol Sci 105:193-200. 2007
    ..This may be a convincing mechanism for the antithrombotic action of NQ12...
  39. ncbi Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents
    Xavier de Leval
    Natural and Synthetic Drugs Research Center, Laboratory of Medicinal Chemistry, University of Liege, B 4000 Liege, Belgium
    J Pharmacol Exp Ther 318:1057-67. 2006
    ..These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration...
  40. ncbi From the design to the clinical application of thromboxane modulators
    Jean Michel Dogne
    Natural and Synthetic Drug Research Centre, Medicinal Chemistry, University of Liege, Belgium
    Curr Pharm Des 12:903-23. 2006
    ..Finally, in the last part we will highlight the latest perspectives in drug design of thromboxane modulators and in their future therapeutic applications such as cancer, metastasis and angiogenesis...
  41. ncbi Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage
    Thibaut Dassesse
    Metastasis Research Laboratory, Center of Experimental Cancer Research, University of Liege, B 4000 Liege, Belgium
    Eur Urol 50:1021-31; discussion 1031. 2006
    ..We investigated the potential involvement of the thromboxane A(2) (TXA(2)) pathway in human prostate cancer (PCa)...
  42. ncbi Mechanisms involved in the antiplatelet effect of C-phycocyanin
    Hui Fen Chiu
    Department of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China
    Br J Nutr 95:435-40. 2006
    ....
  43. pmc Predominant basal directional release of thromboxane, but not prostacyclin, by placental trophoblasts from normal and preeclamptic pregnancies
    S Zhao
    Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA
    Placenta 29:81-8. 2008
    ..To investigate apical and basal releases of thromboxane (TX) and prostacyclin (PGI2) by trophoblasts (TCs) from normal and preeclamptic (PE) placentas...
  44. ncbi Thromboxane A2 synthesis in human erythroleukemia cells
    D A Jones
    Department of Pharmacology, University of Colorado Health Sciences Center, Denver 80262
    Biochem Biophys Res Commun 180:8-14. 1991
    ..Amplification and sequence analysis of a 528 bp cDNA demonstrated virtually 100% identity to a published thromboxane synthase cDNA fragment...
  45. ncbi Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative
    Shiou Chi Cherng
    Department of Nuclear Medicine, Tri Service General Hospital, Taipei, Taiwan, Republic of China
    Eur J Pharmacol 532:32-7. 2006
    ....
  46. ncbi Thromboxane A2 induces itch-associated responses through TP receptors in the skin in mice
    Tsugunobu Andoh
    Department of Applied Pharmacology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
    J Invest Dermatol 127:2042-7. 2007
    ..Thus, thromboxane synthase inhibitor and TP receptor antagonists will be candidates for antipruritic medicines...
  47. ncbi Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers
    Jorge Gracia-Sancho
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, Ciberehd and Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 47:220-7. 2007
    ..Our study was aimed at investigating the role of enhanced AA bioavailability modulating the hepatic vascular tone of cirrhotic livers and identifying which prostanoid is involved...
  48. ncbi Activation of endogenous thromboxane A2 biosynthesis mediates presynaptic inhibition by endothelin-3 of dog stellate ganglionic transmission
    K Kushiku
    Department of Pharmacology, School of Medicine, Fukuoka University, Japan
    J Pharmacol Exp Ther 272:70-6. 1995
    ....
  49. ncbi Dissociation of endothelial cell dysfunction and blood pressure in SHR
    B Tesfamariam
    Department of Pharmacology, Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA
    Am J Physiol 269:H189-94. 1995
    ..In contrast, the thromboxane A synthase inhibitor, dazoxiben, only partially improved abnormal acetylcholine-induced relaxations in aorta from SHR...
  50. ncbi Suppressive effects of F-1322 on the antigen-induced late asthmatic response and pulmonary eosinophilia in guinea pigs
    A Mochizuki
    Pharmaceuticals Research Laboratories, Fujirebio Inc, 51 Komiya cho, Tokyo 192 0031, Hachioji, Japan
    Eur J Pharmacol 430:123-33. 2001
    ..The pharmacological profile of F-1322 indicates that this drug is likely to be useful in the treatment of allergic diseases such as asthma...
  51. ncbi Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery
    K Kawano
    Department of Pharmacology, Hamamatsu University School of Medicine, Japan
    Eur J Pharmacol 374:377-85. 1999
    ..These results suggest that platelet integrin GPIIb-IIIa receptor antagonists are more beneficial than aspirin for the treatment of cerebral thrombosis...
  52. ncbi [The effect of leukotriene C4/D4 receptor antagonist (ONO-1078) and thromboxane A2 synthetase inhibitor (OKY-046) on airway hyperresponsiveness induced by ozone exposure in guinea pigs]
    A Okazawa
    First Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan
    Nihon Kyobu Shikkan Gakkai Zasshi 28:293-9. 1990
    ..These results suggest that leukotriene and thromboxane play an important role in the development of airway hyperresponsiveness induced by ozone exposure in guinea pigs...
  53. ncbi Percutaneous penetration of ozagrel and the enhancement produced by saturated fatty acids
    T Ogiso
    Faculty of Pharmaceutical Sciences, Kinki University, Higashi Osaka, Osaka, Japan
    Biol Pharm Bull 23:844-9. 2000
    ....
  54. pmc Ozagrel hydrochloride, a selective thromboxane A₂ synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice
    Yoshiro Tomishima
    Department of Clinical Chemistry and Informatics, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5 1 Oe honmachi, Chuo Ku, Kumamoto 862 0973, Japan
    BMC Gastroenterol 13:21. 2013
    ..Overdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury. We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced by APAP overdose in mice...
  55. pmc E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the Cl- secretion induced by platelet-activating factor in isolated rat colon
    Hideki Sakai
    Department of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930 0194, Japan
    Br J Pharmacol 136:383-90. 2002
    ..6. These findings suggest that E3040 sulphate is a novel Tx synthase inhibitor, and that E3040 sulphate taken up into the colonic cells by organic anion transporters inhibits the PAF-induced Cl- secretion by blocking a release of TxA2...
  56. ncbi Centrally administered neuromedin U elevates plasma adrenaline by brain prostanoid TP receptor-mediated mechanisms in rats
    Tsuyoshi Sasaki
    Department of Pharmacology, School of Medicine, Kochi University, Nankoku, Kochi 783 8505, Japan
    Eur J Pharmacol 592:81-6. 2008
    ..These results suggest that centrally administered neuromedin U evokes the secretion of adrenaline from the adrenal medulla by brain prostanoid TP receptor-mediated mechanisms in rats...
  57. ncbi Abnormalities of endothelium-dependent responses in mesenteric arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats are improved by chronic treatment with thromboxane A2 synthase inhibitor
    Takayuki Matsumoto
    Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Tokyo, Japan
    Atherosclerosis 205:87-95. 2009
    ..e., NO and EDHF) signaling and reducing EDCF signaling...
  58. pmc Thromboxane synthase immunohistochemistry in inflammatory bowel disease
    E Carty
    Department of Adult and Paediatric Gastroenterology, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary College, London UK
    J Clin Pathol 55:367-70. 2002
    ..Thromboxanes are produced in excess in inflammatory bowel disease. Preliminary reports suggest that ridogrel, a thromboxane synthase inhibitor, is anti-inflammatory and may have therapeutic benefits in patients with ulcerative colitis...
  59. ncbi Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival
    Jean E Abraham
    Cancer Research UK Department of Oncology, University of Cambridge, United Kingdom
    Clin Cancer Res 15:2181-91. 2009
    ..We investigated associations between common germ-line variations in seven genes in the prostaglandin pathway and breast cancer susceptibility and survival among women with invasive breast cancer in the SEARCH study...
  60. ncbi The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase
    Jung Jin Lee
    Department of Pharmacology, Chungnam National University College of Pharmacy, Daejeon, 305 764, Korea
    Arch Pharm Res 33:387-94. 2010
    ..This may contribute to the beneficial effects of paclitaxel on the cardiovascular system...
  61. pmc Thromboxane A2 synthetase inhibitor plus low dose aspirin : can it be a salvage treatment in acute stroke beyond thrombolytic time window
    Gyu Hwan An
    Department of Neurosurgery, National Medical Center, Seoul, Korea
    J Korean Neurosurg Soc 50:1-5. 2011
    ..Ozagrel sodium, a selective thromboxane A2 synthetase inhibitor, has been known to suppress the development of infarction. The antiplatelet effect is improved when aspirin is used together with a thromboxane synthetase inhibitor...
  62. ncbi Biological mechanisms of glioma invasion and potential therapeutic targets
    B B Tysnes
    Department of Anatomy and Cell Biology, University of Bergen, Norway
    J Neurooncol 53:129-47. 2001
    ..This will hopefully render promising new therapeutic targets for gliomas...
  63. ncbi Solution structure of a common substrate mimetic of cyclooxygenase-downstream synthases bound to an engineered thromboxane A2 synthase using a high-resolution NMR technique
    Ke He Ruan
    Vascular Biology Research Center, Division of Hematology, Department of Internal Medicine, The University of Texas Health Science Center, Houston, 77030, USA
    Arch Biochem Biophys 444:165-73. 2005
    ..The NMR technique can be used as a powerful tool to determine the conformations of PGH(2) bound to other COX-downstream synthases...
  64. ncbi Centrally administered N-methyl-d-aspartate evokes the adrenal secretion of noradrenaline and adrenaline by brain thromboxane A2-mediated mechanisms in rats
    Shoshiro Okada
    Department of Pharmacology Graduate School of Medicine, Kochi University, Nankoku, Kochi 783 8505, Japan
    Eur J Pharmacol 586:145-50. 2008
    ..These results suggest that centrally administered N-methyl-d-aspartate induces the secretion of noradrenaline and adrenaline from adrenal medulla by the brain thromboxane A2-mediated mechanisms in rats...
  65. ncbi Gender difference in response to thromboxane A2/prostaglandin H2 receptor antagonism in spontaneously hypertensive rats
    Maria Carolina Acosta Cazal
    Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi 39216 4505, USA
    Gend Med 1:100-5. 2004
    ..As in humans, BP is higher in male spontaneously hypertensive rats (SHRs) than in female SHRs. The mechanism(s) responsible for the higher BP in men and male rats has not been elucidated...
  66. ncbi Effects of endothelin receptor blockade on hypervasoreactivity in streptozotocin-diabetic rats: vessel-specific involvement of thromboxane A2
    Emi Arikawa
    Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada
    Can J Physiol Pharmacol 84:823-33. 2006
    ..These data indicate that an interaction between ET-1 and TxA2 may be involved in mediating the exaggerated vasoconstrictor responses in diabetic arteries. Furthermore, the underlying mechanisms appear to be vessel specific...
  67. ncbi Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis
    V Young
    Biomedical Research Centre, Department of Medicine, Ninewells Hospital and Medical School, University of Dundee, UK
    Rheumatology (Oxford) 41:869-75. 2002
    ..To determine the expression of molecular markers of prostanoid/fatty acid signalling in leucocytes of patients with systemic sclerosis (SSc)...
  68. ncbi Inhibition of TXA synthesis with OKY-046 improves liver preservation by prolonged hypothermic machine perfusion in rats
    Hongzhi Xu
    Department of Biology, University of North Carolia at Charlotte, Charlotte, North Carolina 28223, USA
    J Gastroenterol Hepatol 23:e212-20. 2008
    ..The underlying injury mechanism is not well understood. The present study sought to investigate the role of thromboxane A(2) (TXA(2)) in the pathogenesis of liver injury after prolonged HMP...
  69. ncbi Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity
    Yong Ri Jin
    Research Institute of Veterinary Medicine, Chungbuk National University, Cheongju 361 763, Republic of Korea
    Atherosclerosis 194:144-52. 2007
    ....
  70. ncbi SAR index: quantifying the nature of structure-activity relationships
    Lisa Peltason
    Department of Life Science Informatics, B IT, Rheinische Friedrich Wilhelms Universitat, Dahlmannstr 2, D 53113 Bonn, Germany
    J Med Chem 50:5571-8. 2007
    ..Given a set of active compounds and their potency values, SAR Index calculations can estimate how likely it is to identify structurally distinct molecules having similar activity...
  71. ncbi Hypoxic pulmonary vasoconstriction in isolated blood-perfused rat lung; modulation by thromboxane A2, platelet-activating factor, cysteinyl leukotrienes and endothelin-1
    Stefan Chłopicki
    Department of Pharmacology, Jagiellonian University Medical College, Grzegorzecka 16, PL 31 531, Krakow, Poland
    Pol J Pharmacol 54:433-41. 2002
    ..In summary, in isolated blood-perfused rat lung, TXA2, PAF, cys-LTs and ET-1 seem not to be involved in HPV, whereas we confirm the dominant role of endogenous NO in blunting HPV...
  72. ncbi Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta
    Habib R Ansari
    Department of Physiology and Pharmacology, Center for Interdisciplinary Research in Cardiovascular Sciences, Robert C Byrd Health Science Center, West Virginia University, Morgantown, WV 26505, USA
    Am J Physiol Heart Circ Physiol 293:H3448-55. 2007
    ..Expression of both A(3)AR and COX-1 was located mostly on endothelium of WT and A(3)KO +E aorta. These results demonstrate for the first time the involvement of COX-1 pathway in A(3)AR-mediated contraction via endothelium...
  73. ncbi Radical scavenging glycoprotein inhibiting cyclooxygenase-2 and thromboxane A2 synthase from aloe vera gel
    A Yagi
    Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Gakuen cho, Fukuyama, Hiroshima, Japan
    Planta Med 69:269-71. 2003
    ..The glycoprotein fraction showed a radical scavenging activity against superoxide anion generated by the xanthine-xanthine oxidase system as well as inhibition of cyclooxygenase-2 and reduction of thromboxane A 2 synthase level in vitro...
  74. ncbi Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action
    Kyung Sup Lee
    College of Pharmacy, Chungbuk National University, Cheongju 361 763, Korea
    Arch Pharm Res 29:375-83. 2006
    ..These results suggest that the antiplatelet activity of KR-32570 against collagen-induced platelet aggregation is mediated mainly by inhibiting the release of arachidonic acid, TXA2 synthase, the mobilization of cytosolic Ca2+ and NHE-1...
  75. ncbi Endothelium-dependent contraction induced by nicotine in isolated canine basilar artery--possible involvement of a thromboxane A2 (TXA2) like substance
    H Shirahase
    Department of Pharmacology, Faculty of Medicine, Kyoto University, Japan
    Life Sci 42:437-45. 1988
    ....
  76. ncbi Study of the mechanisms involved in the bradykinin-induced contraction of the pig iris sphincter muscle in vitro
    Mariem El Sayah
    Department of Pharmacology, Centre of Biological Sciences, Universidade Federal de Santa Catarina, Rua Ferreira Lima, 82, SC, 88015 420, Florianopolis, Brazil
    Eur J Pharmacol 458:175-81. 2003
    ....
  77. ncbi Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease
    M Zaitsu
    Department of Pediatrics, Saga Medical School, Saga, Japan
    J Infect Dis 181:1101-9. 2000
    ..Ulinastatin treatment is possibly an additional therapeutic approach to Kawasaki disease...
  78. ncbi The role of thromboxane A2 [TxA2] in liver injury in mice
    H Nagai
    Department of Pharmacology, Gifu Pharmaceutical University, Japan
    Prostaglandins 38:439-46. 1989
    ..v. into the mice, clear elevation of serum GOT and GPT levels and histopathological score of the liver were observed. These results suggest that TxA2 play a role for the onset of CCl4-induced liver injury in mice...
  79. ncbi Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis
    S Kaku
    Department of Pharmacology, Hamamatsu University School of Medicine, Japan
    Eur J Pharmacol 345:185-92. 1998
    ..The novel selective GPIIb/IIIa antagonist YM337 was effective in ameliorating the decrease in patency of the middle cerebral artery and reducing the area of cerebral infarction in monkeys...
  80. ncbi Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids
    P Cozzi
    Business Unit Therapeutics, Laboratory of Chemistry, Pharmacia Farmitalia Carlo Erba, Milan, Italy
    J Med Chem 37:3588-604. 1994
    ..A molecular modeling study concerning the levorotatory enantiomer of 23c (S), TxA2, and representative TxA2 antagonists of different classes led to the definition of a putative pharmacophoric model for the TxA2 receptor ligands...
  81. ncbi Mechanisms of hypotension produced by platelet-activating factor
    F R Laurindo
    Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 4799
    J Appl Physiol 66:2681-90. 1989
    ..PAF-induced release of TxA2 may contribute significantly to these events...
  82. ncbi The role of thromboxane A2 (TxA2) in allergic cutaneous reactions and the effect of (E)-3-[p-(1H-imidazol-1-ylmethyl) phenyl]-2-propenoic acid hydrochloride (OKY-046), a TxA2 synthetase inhibitor
    H Nagai
    Department of Pharmacology, Gifu Pharmaceutical University, Japan
    Prostaglandins Leukot Essent Fatty Acids 35:125-30. 1989
    ..These results suggest a slight role of TxA2 in cutaneous allergic reactions in mice and rats and the efficacy of OKY-046 on Type I and II reactions regardless of the inhibition of TxA2 synthetase activity...
  83. ncbi Pathophysiological role of thromboxane A2 and pharmacological approaches to its inhibition
    H Patscheke
    Institute for Clinical Chemistry, Klinikum Mannheim, University of Heidelberg, FRG
    Z Kardiol 79:151-4. 1990
    ..Agents that combine both principles of action in one compound are also under clinical investigation...
  84. ncbi Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers
    T Uematsu
    Department of Pharmacology, Hamamatsu University School of Medicine, Japan
    J Pharm Pharmacol 48:380-5. 1996
    ..FK070 was concluded to be well tolerated and to provide long-lasting blockade of TXA2 receptors, and plasma concentration-dependent inhibition of TXA2 synthetase in the platelets...
  85. ncbi Abundant expression of thromboxane synthase in rat macrophages
    Y Tone
    Department of Pharmacology, National Cardiovascular Center Research Institute, Osaka, Japan
    FEBS Lett 340:241-4. 1994
    ..Bone marrow, spleen, lung and thymus also expressed the TX synthase gene. These findings suggest the possibility that TXA2 plays a role in the immune system...
  86. ncbi Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum
    K H Ruan
    Vascular Biology Research Center, University of Texas Health Sciences Center, Houston 77030
    J Biol Chem 268:19483-90. 1993
    ..R., and Strobel, H. W. (1988) J. Biol. Chem. 263, 6038-6050), in which the NH2 terminus is oriented toward the cytoplasmic side of the endoplasmic reticulum membrane...
  87. ncbi [Adrenergic stimulation and renal synthesis of prostaglandins in genetically hypertensive rats of the Lyons strain]
    K L Liu
    , URA-CNRS 606, , Lyon
    Arch Mal Coeur Vaiss 83:1237-40. 1990
    ..This effect which was more marked for NE than for PHE did not differ between the 2 strains for 6KPGF but was enhanced for TxB2 in kidney of LH rat.(ABSTRACT TRUNCATED AT 250 WORDS)..
  88. ncbi Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat
    T Kato
    2nd Department of Internal Medicine, Nagoya University School of Medicine, Japan
    Hypertension 15:475-81. 1990
    ....
  89. ncbi In situ localization and regulation of thromboxane A(2) synthase in normal and LPS-primed lungs
    L Ermert
    Department of Pathology, Justus Liebig University Giessen, 35385 Giessen, Germany
    Am J Physiol Lung Cell Mol Physiol 278:L744-53. 2000
    ..These data provide a morphological basis for the understanding of the role of TxA(2) in the regulation of lung bronchial and vascular tone and in immunologic events...
  90. ncbi Endothelial dysfunction augments myogenic arteriolar constriction in hypertension
    A Huang
    Department of Physiology, New York Medical College, Valhalla 10595
    Hypertension 22:913-21. 1993
    ..Thus, the present findings suggest that in early hypertension pressure-induced arteriolar constriction is increased. This seems to be due to an enhanced production of endothelium-derived constrictor factors, primarily prostaglandin H2...
  91. ncbi Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding
    K I Kawano
    Department of Pharmacology, Hamamatsu University School of Medicine, Hamamatsu 431 3192, Japan
    Eur J Pharmacol 417:217-22. 2001
    ..Therefore, the thromboxane A(2) synthase inhibitor allowed a reduction in the dose level of the platelet integrin GPIIb-IIIa receptor antagonist for cerebral thrombosis, which resulted in a reduced risk of bleeding...
  92. ncbi Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung
    M F Bureau
    Unite de Pharmacologie Cellulaire, Institut Pasteur Institut National de la Santé et de la Recherche Medicale, Paris, France
    J Pharmacol Exp Ther 260:832-40. 1992
    ....
  93. ncbi Angiotensin II-induced contractions in human internal mammary artery: effects of cyclooxygenase and lipoxygenase inhibition
    F Stanke-Labesque
    Laboratory of Pharmacology, University of Medicine, LSCPA EA2937, La Tronche, France
    Cardiovasc Res 47:376-83. 2000
    ..This study investigated, in isolated human internal mammary artery, the involvement of the cyclooxygenase and the lipoxygenase pathways of arachidonic acid metabolism in the contraction induced by angiotensin II...
  94. ncbi Inhibitory effect of a peptide leukotriene antagonist ONO-1078 on LTD4- and antigen-induced thromboxane B2 production in guinea pig lungs
    T Obata
    Minase Research Institute, Ono Pharmaceutical Co, Ltd, Osaka, Japan
    Life Sci 52:PL97-102. 1993
    ..These results suggest that ONO-1078 may prevent the antigen-induced production of TxB2 through the blockade of the activation of receptors by endogenously generated peptide leukotrienes...
  95. ncbi Delayed thromboxane or tumor necrosis factor-alpha, but not leukotriene inhibition, attenuates prolonged pulmonary hypertension in endotoxemia
    J X Li
    Department of Pediatrics, University of Alabama at Birmingham 35233 7335, USA
    Am J Med Sci 310:103-10. 1995
    ..Combined thromboxane A2 and TNF alpha blockade may be clinically useful in treatment of advanced sepsis in neonates...
  96. ncbi Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2
    G E Caughey
    Rheumatology Unit, Royal Adelaide Hospital, and Division of Human Immunology, Hanson Centre for Cancer Research, Adelaide, South Australia, Australia
    J Immunol 167:2831-8. 2001
    ..These findings have particular importance with regard to the potential for cardiovascular consequences of COX-2 inhibition...
  97. ncbi Mechanism of immunoreactive atrial natriuretic factor release in an ovine model of endotoxemia
    G Redl
    Department of Anesthesiology, University of Texas Medical Branch, Galveston
    Circ Shock 38:34-41. 1992
    ..The increase in IR-ANF release noted following the administration of LPS in an ovine model does not appear to be related to the early elevations in right heart volumes or atrial distension...
  98. ncbi Expression of cyclooxygenase-2 and thromboxane synthase in non-neoplastic and neoplastic thyroid lesions
    Mary B Casey
    The Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Endocr Pathol 15:107-16. 2004
    ..However, the expression of both COX-2 and TBXAS by thyroid tissue may provide insight into the role of these enzymes in progression from benign to malignant thyroid tumors...
  99. pmc Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects
    Brian D Guth
    Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse 65, Postfach 1755, 88397 Biberach an der Riss, Germany
    Br J Clin Pharmacol 58:40-51. 2004
    ..To characterize the pharmacokinetics of terbogrel, a new combined thromboxane A2 (TxA2) receptor and synthase inhibitor, in healthy human subjects after single or multiple oral administration...
  100. ncbi Effect of OKY-046 (thromboxane A2 synthetase inhibitor) on exercise-induced asthma
    M Hoshino
    Second Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
    J Asthma 28:19-29. 1991
    ..In other words, the fact that TxA2 was a mediator of EIA had been made clear, but it was also found that it had no association as a mediator of leukotrienes (LTC4 and LTB4) in EIA...
  101. ncbi Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency
    N Matijevic-Aleksic
    Division of Hematology, University of Texas Medical School at Houston 77030, USA
    Br J Haematol 92:212-7. 1996
    ....

Research Grants19

  1. Prostaglandin I synthase, Thromboxane A synthase & Prostaglandin E synthase
    Ke He Ruan; Fiscal Year: 2009
    ....
  2. Thromboxane synthases-enzymology and gene regulation
    Lee Ho Wang; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  3. REGULATION OF RENAL FUNCTION AND BP BY THROMBOXANE
    CHRISTOPHER WILCOX; Fiscal Year: 2002
    ....
  4. Aberrant Platelet Mechanisms in Inherited Human Platelet Function Disorders
    ANGARA KONETI RAO; Fiscal Year: 2010
    ..Our studies will provide a wealth of information on platelet mechanisms and on potential new targets for antithrombotic therapy. ..
  5. Prostanoids and hypoxic neonatal pulmonary hypertension
    CANDICE FIKE; Fiscal Year: 2009
    ..The goal of this project is to help us understand why infants develop pulmonary hypertension, determine what happens in the lung blood vessels during disease development, and develop treatments for this disease. ..
  6. SHORT-TERM RESEARCH TRAINING FOR MINORITY STUDENTS
    Charles Wood; Fiscal Year: 2008
    ..The emphasis of this training program in the next five years will be to significantly expand the students' horizons and to recruit students into basic biomedical science. ..
  7. Modeling Folate, One-Carbon Metabolism & DNA Methylation
    Cornelia Ulrich; Fiscal Year: 2007
    ..We plan to make the model generally available to the research community, and anticipate that it will become a useful tool that can be used as an adjunct to experimental investigations and as an aid to study design. ..
  8. POLYMORPHISMS IN PG/COX PATHWAY AND COLORECTAL POLYPS
    Cornelia Ulrich; Fiscal Year: 2003
    ..Finally, we plan to develop a model for integrating information on genetic variability at multiple points in this metabolic pathway. ..
  9. Estrogen Influences on Fetal Adrenocorticotropin
    Charles Wood; Fiscal Year: 2006
    ..abstract_text> ..
  10. NSAID and COX/PG Metabolism and Colorectal Cancer
    Cornelia Ulrich; Fiscal Year: 2009
    ..Ultimately, such information on the metabolic variation will be useful in optimizing NSAIDs and NSAID regimens and will allow individual tailoring of chemoprevention. ..
  11. Prostaglandin Synthesis, Genetics and Colorectal Cancer
    Cornelia M Ulrich; Fiscal Year: 2010
    ..They will also advance tailoring of chemoprevention in a way that maximizes benefit and minimizes toxicity. ..
  12. COX2-Regulated Testosterone Biosynthesis in Male Aging
    XingJia Wang; Fiscal Year: 2009
    ..abstract_text> ..
  13. PATHOGENESIS OF ANTICONVULSANT HYPERSENSITIVITY SYNDROME
    JAMES LEEDER; Fiscal Year: 2003
    ..It is anticipated that the basic experimental paradigm employed for these studies can also be applied to other idiosyncratic toxicities with suspected drug bioactivation and immune etiologies. ..
  14. Genetic Study of Prostaglandin Synthesis/EGFR and Risk of Colorectal Neoplasia
    Cornelia Ulrich; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  15. Ontogeny of Drug Bioactivation and Idiosyncratic ADRs
    JAMES LEEDER; Fiscal Year: 2007
    ..abstract_text> ..
  16. SIGNAL TRANSDUCTION DEFECTS IN HUMAN PLATELETS
    A Rao; Fiscal Year: 2006
    ..Overall, our studies will provide new important insights into the regulation of two key platelet proteins (G-alpha-q and PLC-beta2) involved in platelet signaling and into the signaling mechanisms in platelets. ..
  17. Exercise effects on oxidative damage among women
    Cornelia Ulrich; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  18. PATHOPHYSIOLOGICAL ROLE OF 12-R-LIPOXYGENASE
    ALAN BRASH; Fiscal Year: 2002
    ..abstract_text> ..
  19. NOVEL OXYGENATIONS OF ARACHIDONIC ACID
    ALAN BRASH; Fiscal Year: 2006
    ..These studies will develop new insights into the biochemistry of mammalian cyclooxygenases and as a consequence have practical benefits in development of therapeutics. ..